INMB Company Profile and Key Details

INMB has shown mixed momentum, gaining 8.84% over the past week and -13.51% over the past quarter, though year-to-date performance is up 2.56%. Short-term trend indicators are bullishly aligned (SMA20 -5.06%, SMA50 -11.05%, SMA200 -53.09%). The stock’s 14-day RSI is 44.0 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.03% below its high and over 9.42% above its low. Average 10-day trading volume of 300.96 thousand shares is below the 3-month average of 405.39 thousand, indicating normal recent market interest.

INmune Bio, Inc. has 26.59 million shares outstanding. The public float is 18.72 million shares, elevated short interest at 26.34% of float. This equals 5.98 million shares. The short ratio is 1.42 days. Institutional investors hold 28.14% of the float. Insiders own 24.61%. Moss David J holds 1.29 million shares, Powers Linda F has 210.00 thousand shares and Schroeder Timothy j has 82.19 thousand shares.

INmune Bio, Inc. (NASDAQ:INMB) closed at $1.51 USD, gaining $0.09 (6.34%) from the previous close of $1.42. The stock is currently mid-range between its 52-week high and low $1.38 and $11.64. With a market capitalization of about $40.14 million, INmune Bio, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.74). Key stats such as the average daily volume over the past year has been around 407.55 thousand shares, in line with its 52-week average. Headquartered in Boca Raton, FL, INmune Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David J. Moss, the company employs approximately 13 people and listed since February 04, 2019. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease.

INmune Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.00. This means the shares are trading above this model’s fair value.

INmune Bio, Inc. generated EPS of -$2.14 over the past year. Five-year average earnings growth is -23.07%. Wall Street analysts project EPS growth of 22.73% annually over the next five years. The latest quarter delivered EPS of -$0.24. The next quarter is forecast at -$0.26. Next year's EPS is expected at -$41.69. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $30.00 to $0.60. The high target offers 1886.75% upside. The low target suggests -60.26% downside. The mean target is $15.40. This offers 919.87% upside. INmune Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by -22.58%. The prior quarter beat by -8.11%. Over the last six quarters, Apple has recorded several small beats. These include -19.88% in August 01, 2024.

Our AI price prediction model suggests that INmune Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.32%, with price expected at $1.49 by February 20, 2026, within a range of $1.40 to $1.59 3-Month Outlook: Projected fall of -61.59%, reaching $0.58 by May 06, 2026, with a range of $0.39 to $0.76. 1-Year Outlook: Projected loss of -91.39%, with price at $0.13 by February 05, 2027, within a range of $0.00 to $0.20.

INmune Bio, Inc. (NASDAQ:INMB) shares are flat 2.56% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows INmune Bio, Inc. trading at a premium to the broader market with a P/E of -0.81. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.82, suggesting 1278.81% upside. Our AI forecast model points to short-term weakness (-1.32% over two weeks), a medium-term fall (-61.59% over three months), and a longer-term loss (-91.39% over one year), with expected trading ranges indicating moderate volatility.

INmune Bio, Inc. trades at a P/E ratio of -0.81, slightly below the S&P 500 average, with a price-to-sales ratio of 810.85 and a price-to-book ratio of 1.6 suggesting the stock is closer to book value. The P/FCF stands at -1.29, also above market averages.